ArticleJournal of gastroenterology and hepatology2025
Evaluating Malignant Potential of Gastric Adenomas: The Role of Endoscopic Features and Genetic Alterations.
Article in Journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gastric Adenomas and Mimickers: A Review.Diagnostics (Basel, Switzerland) · 2026Review
- Evaluating Malignant Potential of Gastric Adenomas: The Role of Endoscopic Features and Genetic Alterations.Journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThere is no "gold standard" treatment for gastric adenomas due to uncertainty about their malignant potential. We wanted to understand better the factors contributing to their transformation into malignant tumors by analyzing their long-term development, including endoscopic observations and genetic abnormalities.
methodsA total of 34 gastric tumor specimens from 17 patients were analyzed. All patients initially received a diagnosis of adenoma through a biopsy. Subsequently, eight patients were confirmed to have adenoma, while nine were diagnosed with carcinoma following an endoscopic mucosal dissection. The tumor lesions were isolated using laser-capture microdissection for DNA extraction. Subsequent targeted sequencing of 50 cancer-related genes was performed. The resultant data were compared with the patient's clinical records, and the endoscopic findings, including tumor color, microsurface pattern, and microvascular pattern, were observed.
resultsIn ESD specimens, the most frequently detected gene alterations were in APC (53%), KRAS (18%), TP53 (12%), and FBXW (12%). There were no differences in frequency between final diagnoses, although there was a tendency to detect more gene alterations in cases ultimately diagnosed with adenoma (p = 0.05). Conversely, endoscopic findings of reddish/same color rate (p < 0.01) and MSP/MVP irregular rate (p < 0.05) were higher in cases with a final carcinoma diagnosis at ESD.
conclusionsColor and magnifying NBI during endoscopy help predict malignant transformation when patients are followed up for adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.